WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
- Cowen and Company 34th Annual Health Care Conference
9:20 am ET, March 4 in Boston, MA
- 26th Annual ROTH Conference
12:00 pm PT (3:00 pm ET), March 11 in Laguna Niguel, CA
The webcasts will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay will be available for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a member of the Roche Group.
- Health Care Industry
- Company Earnings
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153